MVEC holiday period closure

On behalf of the MVEC Team, we wish you a very happy and safe holiday season with your loved ones.  

Our team will be taking a break and will return in February to provide you with more vaccine education, resources and events in 2023. We'd love to hear from you if there are any specific vaccine topics you would like to see covered next year! 

We also want to say a huge thank you to all our amazing collaborators who have kindly shared their expert knowledge across a number of important vaccine topics and across all of the MVEC platforms this year! 

If you’re travelling this holiday season, stay safe, make sure your vaccines are up to date and pack your sunscreen and insect repellent! 

Save the date for our next Immunisation Skills Workshop on 20th March 2023!

Following the success of our first Immunisation Skills Workshop, MVEC are pleased to announce the date for our next workshop taking place on Monday, 20th March 2023 

This full day interactive, face to face workshop is MVEC’s newest education opportunity designed to educate and upskill accredited immunisation providers on the principles and processes of managing:  

  • effective vaccine communication  
  • error prevention and management  
  • anaphylaxis and acute stress responses.  

In the workshop, attendees will hear from immunisation experts and be able to put their learnings into practice through participation in simulated scenarios.  

The workshop is not a graded assessment but will account for up to 10 nursing CPD hours and up to 20 points of CPD for pharmacist immunisers (including preparation and reading time).  

Venue: The HELP Precinct, The Royal Children’s Hospital, 50 Flemington Road, Parkville
Time: 8:30am – 4:30pm
Cost: $290.00 (including catering)  

Registrations will open to the public January 16th, 2023 via our events page.

New immunisation reference page: Polio

Polio (poliomyelitis) is caused by a gastrointestinal (gut) infection with one of 3 types of polioviruses (serotypes 1, 2 or 3). Polioviruses are RNA enteroviruses from the Picornaviridae family.

Approximately 70% of polio infections are asymptomatic or present as a non-specific febrile illness. It is estimated that flaccid paralysis occurs in less than 1 percent of all polio cases.

Our new reference page details transmission routes, epidemiology and it's prevention through vaccination.

To view the page in full follow the below link:

MVEC: Polio 

MVEC's Immunisation skills workshop - New date announced

Due to increasing COVID-19 case numbers in Victoria and the implementation of visitor restrictions at the Royal Children’s Hospital (RCH), our Immunisation Skills Workshop due to be held at RCH on September 2, has been rescheduled for Friday 25th November. We look forward to announcing the program details and opening the registration for this event in the coming weeks.

VicSIS update- services have changed

From July 2022 there has been a change to the services delivered by VicSIS (the Victorian Specialist Immunisation Services network). The number of VicSIS clinics and their locations have been reduced with adult services now only offered at Barwon Health, Austin Health, Monash Health and Peter MacCallum Cancer Centre. Due to these changes there may be longer wait times for appointments and patients should be advised of this. 

In addition, VicSIS is no longer funded to support paediatric COVID-19 vaccination. Children aged 15 years and under requiring specialist advice can instead be reviewed via the existing specialist immunisation clinics at The Royal Children’s Hospital and Monash Health. Referrals for these services should continue to be submitted via the VicSIS eReferral portal. 

For further information on VicSIS, refer to the link below: 


ATAGI updated recommendations for a winter dose of COVID-19 vaccine

ATAGI have expanded the groups recommended to receive a COVID-19 winter booster dose to now include:  

  • Any adult (including Aboriginal and Torres Strait Islander) aged 50 years and older   
  • Aged care or disability care residents aged 16 years and older   
  • Individuals aged 16 years and older with severe immunocompromise, disability or complex health need, or those with multiple comorbidities which may increase the likelihood of poorer outcomes.  

In addition, any adult aged 30- 49 years who wishes to reduce the likelihood of COVID-19 infection may also receive a winter booster dose. The interval recommended between a previous COVID-19 infection or previous booster dose and administration of a winter booster dose is 3 months. 

ATAGI has noted with concern that booster dose coverage (first dose and winter dose) has been suboptimal for eligible populations and highlights the importance of vaccination in preventing severe infection and hospitalisation.  

To read the updated recommendations in full, please click on the link below:

ATAGI updated recommendations for a winter dose of COVID-19 vaccine

New immunisation reference page: Typhoid

Typhoid and paratyphoid fever are bacterial infections collectively known as enteric fever, caused by the bacteria Salmonella enterica subspecies serovars Typhi and Paratyphi A, B and C. Symptoms can range from mild to severe, and if untreated, can lead to serious complications or even death. They can include prolonged fever, abdominal symptoms or bacteremia (bacteria in the bloodstream).

Our new reference page outlines the signs and symptoms of typhoid, transmission routes and epidemiology, as well as the vaccines available for disease prevention when travelling to typhoid endemic areas.

To read more follow the link below:
MVEC: Typhoid

New immunisation reference page: Mandatory vaccine directions in Victoria

A vaccine mandate means that proof of vaccination, or an authorised medical exemption, is required in certain settings. In our new reference page, we provide information on the vaccine mandates affecting Victorians, including COVID-19 and influenza directions and “No jab, no play” and “No jab, no pay” legislations. Also included is information on the responsibility of the employee/service provider/individual and medical exemptions.  

For further information, click on the link below: 

MVEC: Mandatory vaccine direction in Victoria

ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination

In response to the emergence of the Omicron variant of COVID-19 disease and it's community transmission within Australia, the Australian Technical Advisory Group on Immunisation (ATAGI) has updated recommendations for the timing of COVID-19 vaccine booster doses.

These updated recommendations are based on strong evidence indicating that booster doses are likely to increase protection against infection with the Omicron variant, as well as reassuring international data on the safety of administering early booster doses.

These recommendations include:

  • all adults (≥ 18 years) should receive a single booster dose of COVID-19 vaccine
  • booster doses can be administered as early as 3 months following the completion of a primary course
  • timely booster doses for pregnant women is recommended
  • immunocompromised individuals who have received a 3-dose primary course should also receive a booster dose 3 months after the date of their 3rd dose
  • Comirnaty (Pfizer) and Spikevax (Moderna) are the preferred brands for booster doses. Vaxzevria (AstraZeneca) can be used as a booster dose for individuals with a contraindication to receiving Comirnaty or Spikevax.

ATAGI also encourages anyone aged 12 years or older who is unvaccinated to receive COVID-19 vaccination as soon as possible.

To read the latest update in full please refer to

ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination

SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI

Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.

The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.

For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:

MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)